Where Is CAR-T Therapy Available in India?

CAR-T is given at a short list of accredited centres, not at every large hospital. Tata Memorial Centre and ACTREC, Christian Medical College Vellore, Amrita Hospitals Kochi, Cytecare and Narayana Health in Bengaluru, and Apollo Cancer Centres have all publicly described CAR-T programmes. Several other private groups run units in the metros. Availability is decided branch by branch.

The reason the list is short is physical, not commercial. A centre needs a leukapheresis unit to collect the T cells, a validated cold-chain route to and from the manufacturing facility, a haematology team trained in cell therapy, and an intensive-care unit able to manage cytokine release syndrome and neurological toxicity at short notice. Very few hospitals in India hold all four together, and a hospital that holds three of them is not a CAR-T centre.

Two Indian CD19-directed products hold market authorisation from the Central Drugs Standard Control Organisation. NexCAR19 (talicabtagene autoleucel), developed by ImmunoACT with IIT Bombay and Tata Memorial Hospital, was approved in October 2023. Qartemi (varnimcabtagene autoleucel), from Immuneel Therapeutics and manufactured at its Bengaluru facility on the Narayana Health City campus, was launched in January 2025 for adult relapsed or refractory B-cell non-Hodgkin lymphoma. Which product a centre administers matters, because the two Indian approvals do not cover exactly the same patients.

Partner hospital and treatment centre are not the same thing

This single distinction saves families a wasted journey. The manufacturer's own directory describes an association with more than 130 hospitals in India, while listing a considerably smaller set as authorised treatment centres. The wider network is about referral and cashless billing arrangements. The narrower list is where cells are actually collected, where the infusion is given, and where intensive care is on hand if the patient becomes unwell in the days afterwards.

So ask the question plainly: is this hospital an authorised treatment centre for the product being proposed, or a partner that will refer us elsewhere? Both answers are legitimate. Only one of them means the treatment happens where you are standing.

There is no self-referral route to CAR-T in India. A haematologist or medical oncologist confirms the diagnosis is a CD19-positive B-cell blood cancer, that at least one earlier line of treatment has failed, and that organ function allows intensive treatment. The centre's cell-therapy team then reviews the file and decides whether to offer a slot.

Families often arrive at a centre with a printout and an appointment request. That is not how the pathway works, and understanding the actual sequence is the difference between weeks lost and weeks saved.

1. Your treating haemato-oncologist raises CAR-T as an option. This normally happens after a relapse, or after a line of treatment has failed, not at diagnosis.
2. The records go to a cell-therapy centre. Pathology, flow cytometry or immunohistochemistry confirming CD19, recent imaging, marrow studies and the complete treatment history.
3. The centre repeats its own eligibility testing. Organ function, cardiac assessment, infection screening, and confirmation that there is no active central nervous system disease.
4. The case is discussed by a cell-therapy or tumour board. A written, itemised cost estimate should come out of this step, not a verbal figure.
5. A slot is allocated and financial clearance is arranged. Apheresis slots and manufacturing capacity are finite, so this is usually where the real waiting happens.
6. Leukapheresis is scheduled. Bridging treatment may be given while the cells are being prepared, if the disease is moving quickly.

A referral being made is not the same as a referral being accepted. Centres decline cases, and they decline them for good clinical reasons. The step-by-step version of this pathway, including the paperwork and what happens when a case is turned down, is set out in Applying for CAR-T: The Referral Pathway Step by Step.

There is no single waiting-time figure, and most of the wait is administrative rather than manufacturing. Referral and record review take days to about two weeks. Eligibility testing takes roughly a week. Slot allocation and financial clearance are the most variable step. Cell preparation is described by the manufacturer as around three to four weeks.

The table below sets out the stages in the order they happen, with what typically stretches each one. It is a shape, not a promise, and every centre will give you its own current numbers.

Two practical points come out of that table. First, the clock that matters most is the one before leukapheresis, because that is the part nobody can compress with money. Second, disease that is moving quickly does not wait politely for a slot, which is why bridging treatment is planned rather than improvised, and why a delayed referral is more costly than a delayed manufacturing batch.

A CAR-T centre is defined by four things being present at the same address: leukapheresis, a validated cold chain to the manufacturing facility, a cell-therapy trained haematology team, and an intensive-care unit that can manage cytokine release syndrome. A hospital missing any one of them is a referrer, not a treatment centre.

• A leukapheresis unit on site. The session that collects the T cells runs four to six hours and needs its own trained staff and machine time.
• A validated cold-chain route. Cells travel to the manufacturing facility and back under controlled conditions, with documented handling at both ends.
• A haematology team with named cell-therapy experience. Ask how many CAR-T patients the treating team has personally managed, not how many the group has treated nationally.
• An intensive-care unit that can act within hours. Cytokine release syndrome and neurological toxicity are managed, not avoided, and tocilizumab should already be stocked.
• Blood bank and transfusion services inside the pathway. Counts fall after conditioning chemotherapy, and support has to be immediate.
• Usually, a bone-marrow transplant programme alongside. The same infrastructure and the same expertise carry both, which is why the two tend to sit together.

None of this is exotic. It is simply why the national list stays short, and why a centre that describes itself as offering the therapy should be able to answer all six points in a single conversation.

Published reporting in August 2026 put the price of NexCAR19 in India at under ₹30 lakh, described in that coverage as roughly one-tenth of CAR-T prices in Western countries. Qartemi's launch coverage in January 2025 described it as priced well below global CAR-T. These figures are indicative, as of August 2026, and come from published sources.

The product price is never the whole bill. Leukapheresis, bridging treatment, lymphodepleting chemotherapy, the hospital admission, intensive care if it is needed, supportive medicines such as tocilizumab, repeat scans, and travel and accommodation near the centre are all billed separately. Two centres quoting the same product price can still produce very different final bills, which is why a written, itemised estimate matters more than a headline figure.

Public and academic centres generally carry the lowest total cost, and some patients are treated inside a trial rather than through the commercial route. What that actually involves, including subsidy routes and how long the public waiting lists run, is covered in Getting CAR-T at a Government Hospital: Subsidies and Waiting Lists.

Insurance treatment of cell therapy varies widely between insurers and between policies, and several products are capped or excluded outright. What has actually been paid, product by product, is set out in Insurance and Scheme Coverage for CAR-T by Product.

Six questions separate a working CAR-T programme from a referral desk. Ask them on the phone, before anyone travels, and ask for the answers in writing wherever money is involved.

1. Which product would be used, and is it approved in India for this exact diagnosis and age group?
2. Is this branch an authorised treatment centre for that product, or a partner hospital that refers elsewhere?
3. How many CAR-T patients has the treating team here personally managed?
4. Do leukapheresis, infusion and post-infusion monitoring all happen at this address?
5. What is the current wait to an apheresis slot, and what bridging treatment would be planned meanwhile?
6. Can we have a written, itemised estimate covering apheresis, conditioning, admission, intensive care and supportive medicines?

A centre that answers all six without hesitation is telling you something useful. So is one that cannot.

If the next step for your family is the paperwork rather than the geography, Applying for CAR-T: The Referral Pathway Step by Step takes the referral apart stage by stage, including what a centre looks for and why cases are declined.

If the question is who pays, start with Insurance and Scheme Coverage for CAR-T by Product for what insurers and schemes have actually settled, and Getting CAR-T at a Government Hospital: Subsidies and Waiting Lists for the public-sector route and its realistic timelines.

For the product itself, NexCAR19: India's First CAR-T Therapy Explained covers what the Indian therapy is, who it is approved for and what has been reported about it. For the wider view across checkpoint inhibitors, biosimilars and the other classes of immune treatment, start from Immunotherapy Medicines Explained, or from the main immunotherapy section.